Substituted pyrimidine derivatives as nicotinic acetylcholinesterase receptor alpha 6 modulator
AssigneesCerevance, Inc., Takeda Pharmaceutical Company Limited
InventorsRoland Werner Burli, Martin Teall, Nicola Brice
Life of this patent
Estimating the term…
Abstract
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts, solvates and prodrugs thereof wherein in, R1, R2, R3, L and X are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy particularly for use in treating disorders associated with nicotinic acetylcholine receptor α6 (nAChRα6) activity.
Claims20
A compound of formula (I):
- or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein:
- X is N or CR4;
- L is a bond, —C(O)—, —C(O)—C(R5)2—, —C(R5)2—, or —C(R5)2C(R5)2—;
- each R1 is independently selected from halo, cyano, C1-C5 alkyl, C1-C5 haloalkyl, C3-C6 cycloalkyl, C3-C6 halocycloalkyl, C1-C5 alkoxy, C1-C5 haloalkoxy, C3-C6 cycloalkoxy, and C3-C6 halocycloalkoxy;
- m is 2, 3, 4 or 5;
- R2 is selected from halo, cyano, C1-C5 alkyl, C1-C5 haloalkyl, C3-C6 cycloalkyl, C3-C6 halocycloalkyl, C1-C5 alkoxy, C1-C5 haloalkoxy, C3-C6 cycloalkoxy, and C3-C6 halocycloalkoxy;
- R3 is selected from a C3-C6 cycloalkyl and 4- to 10-membered heterocyclic group, wherein the cycloalkyl or heterocyclic group is optionally substituted with one, two, three, four or five substituents independently selected from halo, cyano, hydroxy, C1-C5 alkyl, C1-C5 haloalkyl, C3-C6 cycloalkyl, C3-C6 halocycloalkyl, C1-C5 alkoxy, C1-C5 haloalkoxy, C3-C6 cycloalkoxy, C3-C6 halocycloalkoxy, —N(R6)2, and —SO2(R6);
- R4 is selected from hydrogen, halo, cyano, C1-C5 alkyl, C1-C5 haloalkyl, C3-C6 cycloalkyl, C3-C6 halocycloalkyl, C1-C5 alkoxy, C1-C5 haloalkoxy, C3-C6 cycloalkoxy, and C3-C6 halocycloalkoxy;
- each R5 is independently selected from hydrogen, CH3, CH2CH3, and CF3;
- and
- each R6 is independently selected from hydrogen and C1-C3 alkyl, or two R6 together with the nitrogen to which they are attached form a 3- to 6-membered saturated heterocyclic group;
- provided the compound is not:
- 4-methoxy-5-(2-methyl-4-(trifluoromethoxy)phenyl)-N-((1s,4s)-4-methylcyclohexyl)pyrimidin-2-amine;
- 4-methoxy-5-(2-methoxy-4-(trifluoromethoxy)phenyl)-N-((1s,4s)-4-methylcyclohexyl)pyrimidin-2-amine;
- or
- N-cyclopropyl-5-(3,4-dimethoxyphenyl)-4-methyl-pyrimidin-2-amine.
(canceled)
A method of treating or preventing a disease, disorder or condition, wherein the method comprises administering to a patient in need thereof a therapeutically or prophylactically effective amount of a compound of formula (I):
- or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein:
- X is N or CR4;
- L is a bond, —C(O)—, —C(O)—C(R5)2—, —C(R5)2—, or —C(R5)2C(R5)2—;
- each R1 is independently selected from halo, cyano, C1-C5 alkyl, C1-C5 haloalkyl, C3-C6 cycloalkyl, C3-C6 halocycloalkyl, C1-C5 alkoxy, C1-C5 haloalkoxy, C3-C6 cycloalkoxy, and C3-C6 halocycloalkoxy;
- m is 0, 1, 2, 3, 4 or 5;
- R2 is selected from hydrogen, halo, cyano, C1-C5 alkyl, C1-C5 haloalkyl, C3-C6 cycloalkyl, C3-C6 halocycloalkyl, C1-C5 alkoxy, C1-C5 haloalkoxy, C3-C6 cycloalkoxy, and C3-C6 halocycloalkoxy;
- R3 is selected from a C3-C6 cycloalkyl and 4- to 10-membered heterocyclic group, wherein the cycloalkyl or heterocyclic group is optionally substituted with one, two, three, four or five substituents independently selected from halo, cyano, hydroxy, C1-C5 alkyl, C1-C5 haloalkyl, C3-C6 cycloalkyl, C3-C6 halocycloalkyl, C1-C5 alkoxy, C1-C5 haloalkoxy, C3-C6 cycloalkoxy, C3-C6 halocycloalkoxy, —N(R6)2, and —SO2(R6);
- R4 is selected from hydrogen, halo, cyano, C1-C5 alkyl, C1-C5 haloalkyl, C3-C6 cycloalkyl, C3-C6 halocycloalkyl, C1-C5 alkoxy, C1-C5 haloalkoxy, C3-C6 cycloalkoxy, and C3-C6 halocycloalkoxy;
- each R5 is independently selected from hydrogen, CH3, CH2CH3, and CF3;
- and
- each R6 is independently selected from hydrogen and C1-C3 alkyl, or two R6 together with the nitrogen to which they are attached form a 3- to 6-membered saturated heterocyclic group;
- wherein the disease, disorder or condition is associated with nicotinic acetylcholine receptor α6 (nAChRα6) activity:
- or wherein the disease, disorder or condition has dysregulation of dopamine, noradrenaline or serotonin as a key pathological mechanism;
- or wherein the disease, disorder or condition is selected from a movement disorder, dystonia, dyskinesia, Parkinson's disease, Huntington's disease, a psychiatric disorder, an addiction disorder, and a non-motor symptom of Parkinson's disease.
18-21. (canceled)
Dependencies are inferred from the claim text.